Nu-Med Plus, Inc. (NUMD) Comparison with companies in other sectors?

Nu-Med Plus, Inc. has a share price of 83.55M. You can analyze Nu-Med Plus, Inc. (NUMD) competitors across different market sectors through stock heatmaps.

What are NUMD's NET and operating margins?

Nu-Med Plus, Inc. (NUMD) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does NUMD's earnings per share (EPS) trend reflect its financial momentum?

Nu-Med Plus, Inc. (NUMD) EPS is 0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Nu-Med Plus, Inc. is 5.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Nu-Med Plus, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Nu-Med Plus, Inc. like P/E which is -61.12, P/B which is -19.42, and PEG which is -1.43. Compare them with sector averages to evaluate if the stock is priced fairly.

Nu-Med Plus, Inc.

NUMD•PNK

Healthcare

Medical - Devices

$0.05

$0.00(0.00%)

Fundamental Analysis of Nu-Med Plus, Inc. (NUMD)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.01

P/E Ratio

5.00

ROE

0.35%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.18M

Shares OutstandingTotal number of shares issued

$83.55M

Book Value/ShareNet worth per share

$-0.00

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.01

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

35.32%

ROAReturn on total assets

-729.17%

ROCEReturn on capital employed

29.44%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.00

Cash/ShareCash and equivalents per share

$0.00

FCF YieldFree cash flow as percentage of market cap

-0.11%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for NUMDFinancial Ratios Analysis details for NUMD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for NUMDSector Benchmarking details for NUMD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Nu-Med Plus, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Nu-Med Plus, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Nu-Med Plus, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Nu-Med Plus, Inc.

For Nu-Med Plus, Inc., essential financial indicators include EPS 0.01, PE 5.00, and ROE 0.35. These key ratios reveal insights into Nu-Med Plus, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Nu-Med Plus, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Nu-Med Plus, Inc.

Metrics like Net Margin - and ROA -729.17% shed light on how well Nu-Med Plus, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Nu-Med Plus, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Nu-Med Plus, Inc.

Using ratios such as P/B Ratio -19.42 and PEG Ratio -1.43, investors can assess whether Nu-Med Plus, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Nu-Med Plus, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Nu-Med Plus, Inc.

Financial health indicators, such as Debt/Equity Ratio -0.46 and Cash Flow $-0.00, provide a snapshot of Nu-Med Plus, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Nu-Med Plus, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Nu-Med Plus, Inc.

Investing in Nu-Med Plus, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Nu-Med Plus, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;